MARLBOROUGH, Mass., March 5, 2009 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women today announced that it has received a final order for 14 Selenia™ digital mammography systems with service contracts from Tromp Medical, the Hologic dealer in The Netherlands. This is the last of four order phases in The Netherlands Breast Cancer Screening Tender.
The tender process started in 2006 with three digital mammography and three computed radiography vendors bidding for the business. In the end Hologic was awarded 100 percent of the digital mammography systems in the tender. The last of the 65+ digital mammography systems awarded under the tender will be installed by the end of 2010.
"I want to congratulate the radiology professionals in The Netherlands for their foresight and dedication to women's health," said Jack Cumming, chairman and chief executive officer of Hologic. "The Netherlands was the first country in the world to install a commercial version of the Selenia digital mammography system. With this award, more than 130 Selenia digital mammography and Selenia Dimensions three-dimensional digital breast tomosynthesis systems will be installed in the country and more than one million Dutch women a year can be screened for breast cancer using Hologic digital mammography systems. This is a remarkable feat for a country with a screening population of less than two million women between the ages of 50 to 75."
"A tender of this magnitude involves the hard work of many people," Cumming noted. "In addition to the Tromp Medical Team, we are thankful to the following Netherland organizations - BoBWest, SBBZWN, Bevolkingsonderzoek Midden-West, Bevolkingsonderzoek Zuid, SVOB, SVOKON and BBNN - for believing in Hologic technology."
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications.
Forward Looking Disclaimer
This News Release contains forward-looking information that involves risks and uncertainties, including statements about expectations for future Selenia system orders in The Netherlands. There can be no assurance that these orders will be awarded to Hologic. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such data or statements is based. Certain factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission.
Note: Selenia™ and Selenia™ Dimensions™ are trademarks of Hologic in the United States and other countries.
Publicity and Advertising Specialist
Director of Marketing